HC Wainwright & Co. Reiterates Buy on Ocuphire Pharma, Maintains $20 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Matthew Caufield has reiterated a 'Buy' rating on Ocuphire Pharma (NASDAQ:OCUP) and maintained a $20 price target.
August 14, 2023 | 10:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ocuphire Pharma's stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and a $20 price target.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, the reiteration of a 'Buy' rating and a maintained price target of $20 by HC Wainwright & Co. for Ocuphire Pharma indicates a positive outlook for the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100